Want to see FENC full AI Analyst Report?
FENC Stock Chart & Stats
$6.79
-$0.02(-0.33%)
At close: 4:00 PM EST
$6.79
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$5.65 - $11.31
Previous Close$6.08
Volume58.66K
Average Volume (3M)239.00K
Market Cap
$364.74M
Enterprise Value$178.44
Total Cash (Recent Filing)$40.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding34,737,030
10 Day Avg. Volume171,391
30 Day Avg. Volume238,999
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.28
Price to Sales (P/S)4.93
P/FCF Ratio-17.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.50Price Target Upside128.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.26
Revenue Forecast (FY)$68.48M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Revenue ScaleVery high gross margins (~92%) combined with meaningful TTM revenue (~$51.2M) indicate attractive product economics that should allow incremental sales to flow to the bottom line as SG&A and R&D scale more slowly than revenue, supporting durable margin expansion as adoption grows.
Commercial Traction And HEARS Hub MomentumSustained commercial acceleration (six quarters of sales growth, Q1 +73% YoY) and rapid HEARS hub throughput (+48% QoQ, ~80% conversion/adherence) reflect scalable distribution and clinical workflow integration, a durable driver for mid-term adoption across pediatric and adult oncology settings.
De-risked Balance Sheet With No DebtA zero-debt capital structure and positive equity materially reduce financial distress risk, providing flexibility to invest in commercialization and clinical programs without immediate refinancing pressure, strengthening multi-quarter runway while the company scales PEDMARK adoption.
Bears Say
Persistent Cash BurnAlthough improved versus prior periods, consistent negative operating and free cash flow (~-$7.9M TTM) means the business is not yet self-funding; continued burn increases reliance on existing cash, operational execution, or external financing if revenue growth or collections dip, posing a sustained liquidity risk.
Ongoing Net Losses And Negative ROETrailing losses (TTM net loss ~$8.8M) and deeply negative return on equity (~-55%) show the company has yet to convert strong unit economics into aggregate profitability; sustained negative returns can erode shareholder value unless operating leverage and cash flow turn sustainably positive.
Front-loaded And Elevated 2026 Operating ExpensesManagement plans materially higher, front-loaded OpEx for 2026 (~$50M with >60% in H1) to build commercial capacity; while intended to accelerate adoption, this raises short-term cash burn and execution risk if sales cadence or reimbursement lags, potentially necessitating further cost control or funding.
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $5.65 and its highest was $11.31 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $364.74M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.054.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,737,030 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 36.484%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (128.28% Upside)
$15.50 (128.28% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
54.78%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
FENC Stock 12 Month Forecast
Average Price Target
$15.50
▲(128.28% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Ownership Overview
10.31% Insiders
4.76% Mutual Funds
― Other Institutional Investors
78.33% Public Companies and
Individual Investors